The Foundation Louis-Jeantet has assigned to Luigi Naldini, director of the Institute of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), and professor at the University Vita-Salute San Raffaele, the Louis-Jeantet prize 2019 “for his pioneering research, which has brought gene therapy from the experimental context to the first clinical applications, thanks to which we have already treated patients with different genetic diseases”
Since it was launched in 1986 up to the present, explains a note from the Foundation, the Prize Louis-Jeantet were attributed to 90 researchers of international reputation, of these 12 are subsequently received the Nobel Prize for physiology or medicine, or the Nobel Prize for chemistry. Together with Luigi Naldini, the prize went also to Botond Roska, one of the founder directors of the Institute of Ophthalmology Clinical and Molecular in Basel (IOB), to the discovery of the basic principles of the processing of the visual information and the development of therapeutic strategies for the treatment of defects of the retina.
Luigi Naldini degree in Medicine and Surgery at the University of Turin, and obtained a phd from the University La Sapienza of Rome. Over the years he has received several awards, including the Outstanding Achievement Award from the american Society of gene and cell therapy in 2014 and the ESGCT in 2015, the prize Jiemenz Diaz in 2016 and the Van Beutler Award of the american Society of hematology in 2017.
Numerous awards underline how in the last twenty years, Luigi Naldini has been a pivotal figure in the development and application of lentiviral vectors for gene transfer. These, in addition to being among the most used tools in the field of biomedical research, are showing safety and efficacy in clinical trials for the treatment of severe genetic diseases and for some types of cancer. The experimental research of Luigi Naldini, the statement concluded, “continue to propose new and innovative solutions to further improve the efficacy and safety of gene therapy, such as the editing of targeted genes. These studies open the way to correction, rather than the replacement of genes, an approach that is potentially revolutionary in the ability to expand substantially the objectives and the power of genetic manipulation”..